Drugs that contain Boceprevir

1. Drug name - VICTRELIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(2 years from now)

CN1633446A MERCK SHARP DOHME New Peptide For As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Aug, 2010

(12 years ago)

CN102206247B MERCK SHARP DOHME A Compound Provided With Hcv Ns3/Ns4A Protease Inhibiting Activity
Aug, 2018

(4 years ago)

CN102206247A MERCK SHARP DOHME As Hepatitis C Virus Ns3 Protease Inhibitor Of Novel Peptide
Aug, 2018

(4 years ago)

IN206985B MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2021

(1 year, 2 months ago)

IN200300089P4 MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2021

(1 year, 2 months ago)

EP1481000B1 MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jan, 2023

(3 months from now)

EP1481000A2 MERCK SHARP DOHME Novel Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jan, 2023

(3 months from now)

EP1385870A2 MERCK SHARP DOHME Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

EP1385870B1 MERCK SHARP DOHME Peptides As Ns3-Serine Protease Inhibitors Of Hepatitis C Virus
Jul, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602 MERCK SHARP DOHME Administration of HCV protease inhibitors in combination with food to improve bioavailability Mar, 2027

(4 years from now)

US7772178 MERCK SHARP DOHME Pharmaceutical formulations and methods of treatment using the same Nov, 2027

(5 years from now)

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
200MG CAPSULE;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.